These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26813076)

  • 21. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
    Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
    Lai X; Friedman A
    BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.
    Jung T; Haist M; Kuske M; Grabbe S; Bros M
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells.
    Herraiz C; Journé F; Ghanem G; Jiménez-Cervantes C; García-Borrón JC
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2244-52. PubMed ID: 23000456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
    Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
    Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
    Namikawa K; Ito T; Yoshikawa S; Yoshino K; Kiniwa Y; Ohe S; Isei T; Takenouchi T; Kato H; Mizuhashi S; Fukushima S; Yamamoto Y; Inozume T; Fujisawa Y; Yamasaki O; Nakamura Y; Asai J; Maekawa T; Funakoshi T; Matsushita S; Nakano E; Oashi K; Kato J; Uhara H; Miyagawa T; Uchi H; Hatta N; Tsutsui K; Maeda T; Matsuya T; Yanagisawa H; Muto I; Okumura M; Ogata D; Yamazaki N
    Cancer Med; 2023 Sep; 12(17):17967-17980. PubMed ID: 37584204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma Treatments: Advances and Mechanisms.
    Marzuka A; Huang L; Theodosakis N; Bosenberg M
    J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma: What do all the mutations mean?
    Davis EJ; Johnson DB; Sosman JA; Chandra S
    Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conjunctival Melanoma: Current Treatments and Future Options.
    Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
    Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
    Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
    J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
    Boni A; Cogdill AP; Dang P; Udayakumar D; Njauw CN; Sloss CM; Ferrone CR; Flaherty KT; Lawrence DP; Fisher DE; Tsao H; Wargo JA
    Cancer Res; 2010 Jul; 70(13):5213-9. PubMed ID: 20551059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
    Lo RS; Shi H
    Methods Mol Biol; 2014; 1102():163-74. PubMed ID: 24258979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.